Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit
- One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients,...
- One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients,...
TUCSON, Ariz., Sept. 04, 2021 (GLOBE NEWSWIRE) -- In a letter to American Medical Association president Gerald Harmon, M.D., the...
TUCSON, Ariz., Sept. 04, 2021 (GLOBE NEWSWIRE) -- COVID-19 vaccine mandates are proliferating as a condition for employment or education,...